ABSIAbsci Corporation
Is the business good?
Margins compressing. That is the only one of 4 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Operating margin has narrowed over the past few years, profitability per dollar of sales is eroding.
Where this answer is blind. The F-score rewards improvement, so an already-elite company can score mid-pack.
How good a business is ABSI?
Absci Corporation keeps −8085% of every revenue dollar as operating profit, against −77% for the median Biotechnology name.
Operating margin · Biotechnology median −77% · 12 months to Q2 2026
- Share count, year on year
- +23%
Share count, year on year · shareholders own a smaller slice than a year ago
- R&D as % of revenue
- 5540%
R&D as % of revenue
| Year | Operating margin |
|---|---|
| FY2020 | −278% |
| FY2021 | −1573% |
| FY2022 | −1857% |
| FY2023 | −2020% |
| FY2024 | −2402% |
| FY2025 | −4297% |
Details›
- Operating margin12 months to Q2 2026
- −8085%
- Net margin12 months to Q2 2026
- −7756%
- Free cash flow margin
- −6994%
- R&D as % of revenue
- 5540%
- Revenue, trailing twelve months
- $1.6M
- Free cash flow, trailing twelve months
- −$109M
- Net income, trailing twelve months
- −$121M
Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.